Alzheon posted positive results from the company’s Phase II biomarker trial on ALZ-801 (valiltramiprosate) in patients diagnosed with neurodegenerative disorders such as Alzheimer’s disease.
The U.S. antitrust regulator asked Biogen Inc. to present documents related to the approval and marketing of the company’s Alzheimer’s disease treatment, the drugmaker disclosed in a filing.
On the strength of data from Alzamend Neuro’s Phase I study of its lead compound AL001 being developed for the treatment of Alzheimer’s disease, the company is looking to commence a Phase II multiple ascending dose study for that indication during the second quarter of 2022.
Alzheimer’s patient groups, disappointed by Medicare’s plan to sharply limit coverage of new drugs for the brain-wasting disease, are planning publicity and lobbying campaigns to protest a proposal they say could delay their use for 10 years.
South Korean biotechnology firm ABL Biotechnologies signed a global licensing and exclusive collaboration agreement with Sanofi to develop and commercialize a new therapy candidate for Parkinson’s disease.
Biogen shares fell on January 12 after the Centers for Medicare and Medicaid Services (CMS) issued its draft national coverage decision for the company’s controversial Alzheimer’s drug Aduhelm.
BioSpace looks at the 10 biggest drug approvals of 2021, headlined by Biogen’s Aduhelm (aducanumab) for Alzheimer’s disease and Pfizer and BioNTech’s COVID-19 vaccine Comirnaty.
BioSpace reviews the 10 biggest drug approvals of 2021, headlined by Biogen’s Aduhelm (aducanumab) as the first drug approved for Alzheimer’s disease in almost 20 years.
Scientists have pondered possible linkages between COVID-19 and the onset of Parkinson’s disease for more than a year, and a new report published in ACS Chemical Neuroscience details that correlation.
Massive layoffs could be headed to Biogen due to the disappointing rollout of the company’s Alzheimer’s drug Aduhelm that generated only a few million dollars in revenue over the past two quarters.
